CHUGAI INNOVATION DAY 2023
claude.iconA summary of CHUGAI INNOVATION DAY 2023 is as follows
As part of its growth strategy "TOP I 2030," Chugai is promoting "RED SHIFT" to strengthen research and early development.
The use of generative AI technology in the medical and healthcare fields was discussed.
Applications in medical language processing from drug discovery to clinical practice
Impact on patient communication
Reduction of document work
Web 3.0 and the use of the digital twin in healthcare were discussed.
Development of an automated treatment system with a digital twin for the cardiovascular system
Building a Disease Prevention Digital Twin by Integrating Multilayered Biological Information
Disease prevention based on genomic cohorts
The Distributed Innovation Commons was discussed.
The Importance of Self-Sovereign Identity
Social Contributions and Rewards of Curation
DAO Utilization and Challenges
Chugai's In-House DAO Initiatives
Connections and Incentive Design for Patients with Rare Diseases
Overall, the conference was a lively discussion on how to utilize the latest technologies such as generative AI, digital twin, and Web 3.0 in the medical and healthcare fields.
RED SHIFT
Chugai positions RED SHIFT) as one of the key drivers of its growth strategy "TOP I 2030". RED SHIFT: RED is a collective term for Research and Early Development. By focusing management resources on RED functions, including research, early clinical development, and the portion of pharmaceutical functions related to early development, and by expanding investment, the company aims to enhance its translational research capabilities from drug discovery to PoC acquisition, which is the source of value creation, and improve R&D output.
Frontiers in Medicine and Healthcare Using Generated AI Technology.
Chat GPT and other generative AI technologies are expected to be used in the medical and healthcare fields. This session will introduce efforts to utilize generative AI technology in the diagnosis and optimization of disease diagnosis and treatment, and in streamlining the drug discovery process, and will provide insights and ideas for further innovation as well as issues that need to be resolved in terms of technology, regulations, and ethics.
Mechanism of Generation AI and its Application to Medical and Health Care [Daisuke Okanohara
Novel Medical Language Processing with Generative AI: From Drug Discovery to Clinical Practice [Eiji Aramaki
self-supervised learning
'A supervised study question where you can get as many correct answers as you want for free.'
Nice way of explaining it. I'll copy that.nishio.icon
This "cost of getting it right" isn't really understood.
How do we ensure correctness when it is beyond human understanding?
peripheral neuropathy
Difficult to take with data
The cost of having a doctor ask the question "Do you have peripheral neuropathy?" every time and data is expensive.
From natural language
Arakawa: "The information value of small communities increases."
Because the data on the Web has been dug up.
Increased importance of personal experience
→Episode Bank
Will AI take the job of communicating with patients?
Better to think of it as a tool.
The tools will have to change the way we work.
The to N communication as it has always been will be streamlined by the generative AI and move to more personalized communication.
Similar to the culture of donations abroad.
Japan has few people who share their experiences, similar to how few people donate money.
Reduction of document work
AI pre-processes routine questions.
New Era of "Healthcare x Digital" Pioneered by Web 3.0 and Digital Twin.
Digital Twin is a technology that uses IoT to acquire information from the real world and reproduce the environment of real space within cyberspace, making it possible to understand and analyze the situation in real space and make predictions through simulations. On the other hand, Web 3.0, the next generation Internet technology, is also expected to serve as a foundation for independent and decentralized organizations that accelerate open innovation. How can these technologies be used to revolutionize the drug discovery process and realize personalized medicine? We will introduce cutting-edge research and initiatives and discuss the ideal vision of the future.
Research and development for social implementation of an innovative automated cardiac disease treatment system using a digital twin of the cardiovascular system Kazunori Kamimura. Construction of a Digital Twin for Disease Prevention by Integrating Multilayered Biological Information [Yoshinori Murakami
National Cardiovascular Center
cardiovascular disease
Cardiovascular disease is a major cause of need for care
It's also a large percentage of health care costs, larger than cancer.
Prognosis for heart failure is the same as for cancer.
But only one specialist is available for every 100 patients.
Need to improve efficiency through IT technology → Digital Twin
The dog's digital twin allowed me to estimate the results of the infusion treatment.
A "self-driving car" approach to heart failure treatment
There is a 12-year gap between average life expectancy and healthy life expectancy
Cancer can reduce medical costs by 30% through prevention.
Education budget 5.5 trillion yen
Disease prevention based on genomic cohort
Collected with permission from company health inspections
Consent rate for participation, over 90%.
Only Japan mandates interest in healthy business people.
Good quality data can be obtained.
Polygenic Risk Score
High-risk groups are identified
Five times the risk for the unlucky 1% of people with the right genes.
Competition for funding
Incentive redesign
Self-sovereign identity
Decision to provide attributes of your own volition
Curation is also a social contribution, an asset, a commons
There is no incentive design to give rewards to the people who make these.
Challenges to DAOs not being created
Lack of recognition
A bad case of bad publicity
Human Resource Issues
Featuring aspects of tokens and cryptocurrencies gives a bad impression.
It is important to look at the "decentralized" approach from a broader perspective
There are spin-out ventures.
But not financially independent.
Pfizer, for example.
Dependent on the support of the wealthy
It is important to involve various stakeholders
What if pharmaceutical companies utilize DAO?
Go in centrally at first and then expand to a diverse community.
Chugai Pharmaceutical
I'm considering it.
Patient DAO
Researcher's DAO
Can you drive without an administrator?
Some kind of curation or community manager is needed.
If you start small, you need someone to direct.
Based on what you want to do, you could consider whether you want to do it centrally or more decentrally.
Not all use cases can be completely decentralized just by incentive design like Bitcoin.
Yes, yes,組織形態はツールであってそれ自体が目的なのではないということねnishio.icon The choice of organizational forms other than corporations and university corporations is becoming more available, and new tools are being added.
rare disease
Patients themselves are fragmented and isolated
As for financial feedback.
Featuring virtual currency aspects is problematic due to the high volatility of prices
A membership-like NFT would be more suitable for this purpose.
Example of [Yamakoshi DAO
---
This page is auto-translated from /nishio/CHUGAI INNOVATION DAY 2023 using DeepL. If you looks something interesting but the auto-translated English is not good enough to understand it, feel free to let me know at @nishio_en. I'm very happy to spread my thought to non-Japanese readers.